company background image
PZRX

PhaseRx OTCPK:PZRX.Q Stock Report

Last Price

US$0.0002

Market Cap

US$2.3k

7D

0%

1Y

100.0%

Updated

19 Dec, 2023

Data

Company Financials

PZRX.Q Stock Overview

PhaseRx, Inc., a biopharmaceutical company, engages in developing a portfolio of products for the treatment of inherited enzyme deficiencies in the liver using intracellular enzyme replacement therapy.

PZRX.Q fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

PhaseRx, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for PhaseRx
Historical stock prices
Current Share PriceUS$0.0002
52 Week HighUS$0.0003
52 Week LowUS$0.0001
Beta0
1 Month Change0%
3 Month Changen/a
1 Year Change100.00%
3 Year Change-88.57%
5 Year Change-92.86%
Change since IPO-100.00%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

PZRX.QUS BiotechsUS Market
7D0%-0.06%2.1%
1Y100.0%9.8%30.4%

Return vs Industry: PZRX.Q exceeded the US Biotechs industry which returned 2.3% over the past year.

Return vs Market: PZRX.Q exceeded the US Market which returned 23.5% over the past year.

Price Volatility

Is PZRX.Q's price volatile compared to industry and market?
PZRX.Q volatility
PZRX.Q Average Weekly Movementn/a
Biotechs Industry Average Movement11.7%
Market Average Movement6.0%
10% most volatile stocks in US Market16.7%
10% least volatile stocks in US Market3.0%

Stable Share Price: PZRX.Q has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine PZRX.Q's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
2006n/aRobert Overell

PhaseRx, Inc., a biopharmaceutical company, engages in developing a portfolio of products for the treatment of inherited enzyme deficiencies in the liver using intracellular enzyme replacement therapy. The company develops its products based on its proprietary Hybrid mRNA technology platform, which allows the synthesis of missing enzyme inside the cell. Its therapeutic urea cycle disorder programs under development include PRX-OTC to treat ornithine transcarbamylase deficiency; PRX-ASL to treat argininosuccinate lyase deficiency; and PRX-ASS1 to treat argininosuccinate synthetase deficiency.

PhaseRx, Inc. Fundamentals Summary

How do PhaseRx's earnings and revenue compare to its market cap?
PZRX.Q fundamental statistics
Market capUS$2.34k
Earnings (TTM)-US$13.89m
Revenue (TTM)n/a

0.0x

P/S Ratio

0.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PZRX.Q income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$13.89m
Earnings-US$13.89m

Last Reported Earnings

Sep 30, 2017

Next Earnings Date

n/a

Earnings per share (EPS)0
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0.0%

How did PZRX.Q perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.